New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 11, 2012
05:31 EDTELN, BIIBBiogen, Elan TYSABRI data at ECTRIMS reaffirms positive effects for MS
Biogen Idec (BIIB) and Elan (ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28TH Congress of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS, in Lyon, France, Oct. 10-13. The data will further establish the benefits of TYSABRI in reducing relapse rates and slowing disease progression.
News For BIIB;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.
November 13, 2014
10:42 EDTBIIBSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
November 12, 2014
08:13 EDTBIIBBoston Biotech to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use